[go: up one dir, main page]

IL309813A - Antisense oligonucleotide (aso) gene inhibition and treatment - Google Patents

Antisense oligonucleotide (aso) gene inhibition and treatment

Info

Publication number
IL309813A
IL309813A IL309813A IL30981323A IL309813A IL 309813 A IL309813 A IL 309813A IL 309813 A IL309813 A IL 309813A IL 30981323 A IL30981323 A IL 30981323A IL 309813 A IL309813 A IL 309813A
Authority
IL
Israel
Prior art keywords
aso
treatment
antisense oligonucleotide
gene inhibition
inhibition
Prior art date
Application number
IL309813A
Other languages
Hebrew (he)
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of IL309813A publication Critical patent/IL309813A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/34Allele or polymorphism specific uses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL309813A 2021-07-15 2022-07-13 Antisense oligonucleotide (aso) gene inhibition and treatment IL309813A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163222336P 2021-07-15 2021-07-15
US202163224362P 2021-07-21 2021-07-21
PCT/US2022/073668 WO2023288240A1 (en) 2021-07-15 2022-07-13 Antisense oligonucleotide (aso) gene inhibition and treatment

Publications (1)

Publication Number Publication Date
IL309813A true IL309813A (en) 2024-02-01

Family

ID=82850241

Family Applications (1)

Application Number Title Priority Date Filing Date
IL309813A IL309813A (en) 2021-07-15 2022-07-13 Antisense oligonucleotide (aso) gene inhibition and treatment

Country Status (8)

Country Link
EP (1) EP4370133A1 (en)
JP (1) JP2024525837A (en)
KR (1) KR20240037996A (en)
AU (1) AU2022312494A1 (en)
CA (1) CA3224471A1 (en)
IL (1) IL309813A (en)
MX (1) MX2024000636A (en)
WO (1) WO2023288240A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024233248A2 (en) * 2023-05-05 2024-11-14 Vanda Pharmaceuticals Inc. Antisense oligonucleotide (aso) gene inhibition and treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014246667A1 (en) * 2013-04-04 2015-11-19 Olivia Newton-John Cancer Research Institute Methods of treating diseases characterized by excessive Wnt signalling
WO2017214463A1 (en) * 2016-06-09 2017-12-14 The Regents Of The University Of California Compositions and methods for treating cancer and biomarkers to detect cancer stem cell reprogramming and progression

Also Published As

Publication number Publication date
AU2022312494A1 (en) 2024-01-18
JP2024525837A (en) 2024-07-12
CA3224471A1 (en) 2023-01-19
WO2023288240A1 (en) 2023-01-19
MX2024000636A (en) 2024-02-06
AU2022312494A9 (en) 2024-01-25
WO2023288240A9 (en) 2023-02-23
KR20240037996A (en) 2024-03-22
EP4370133A1 (en) 2024-05-22
WO2023288240A8 (en) 2023-12-14

Similar Documents

Publication Publication Date Title
WO2013086444A3 (en) Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human lmna
IL274023A (en) Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases
MX2021014868A (en) OLIGONUCLEOTIDES AND METHODS OF USE FOR THE TREATMENT OF NEUROLOGICAL DISEASES.
MX358603B (en) Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene.
WO2010138806A3 (en) Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
IL309813A (en) Antisense oligonucleotide (aso) gene inhibition and treatment
IL288259A (en) Modified gapmer oligonucleotides and methods of use
EP4069256A4 (en) Antisense oligomers for treatment of conditions and diseases
MX2021009135A (en) Oligonucleotides matching col7a1 exon 73 for epidermolysis bullosa therapy.
IL279692A (en) Composition comprising antisense oligonucleotide and use thereof for treatment of duchenne muscular dystrophy
GB202003618D0 (en) Gene Therapy
IL285867A (en) Antisense oligomers for treatment of conditions and diseases
MX2017014855A (en) Antisense oligonucleotides to treat dystrophic epidermolysis bullosa.
IL309445A (en) Pikfyve antisense oligonucleotides
EP3384028A4 (en) ANTISENSE OLIGONUCLEOTIDE (ASO) INHIBITORS DIRECTED AGAINST THE MONOCARBOXYLATE 4 CARRIER (MCT4) AS THERAPEUTIC AGENTS IN THE TREATMENT OF CANCER
IL307787A (en) Antisense oligonucleotides and their use for treatment of neurodegenerative disorders
IL318200A (en) Gene therapy for fam161a-associated retinopathies and other ciliopathies
IL306119A (en) Gene therapy for treating beta-hemoglobinopathies
GB202300865D0 (en) Delivery of oligonucleotides
IL287608A (en) Intrathecal and intravenous combination gene therapy for the treatment of infantile batten disease
GB202003109D0 (en) Gene therapy
GB202002202D0 (en) Gene therapy
IL313660A (en) Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas
GB202215198D0 (en) Gene therapy treatment
WO2023245118A3 (en) Treatment of ms4a4e related diseases and disorders